New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
05:34 EDTSNYSanofi, Transgene launch construction phase of new bioproduction platform
Sanofi and Transgene SA announced that they have launched the construction phase of the manufacturing platform dedicated to the production of viral vectors, such as Transgene’s MUC1 targeted cancer immunotherapy, TG4010. In March 2013, the companies announced a long-term collaboration agreement to build the unit, which is to be constructed on the Genzyme Polyclonals site in Lyon, an important French biopharmaceutical cluster. The companies together will invest approximately EUR 10M in the production unit over an expected two-year timeframe, of which Transgene's share will be approximately EUR 5M. This dedicated platform will be Sanofi’s exclusive property and will enable to produce a new breakthrough class of APIs.
News For SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
11:19 EDTSNYSanofi reportedly ready to make acquisitions in animal medicine, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use